Details for Patent: 11,103,513
Which drugs does patent 11,103,513 protect, and when does it expire?
Patent 11,103,513 protects BIJUVA and is included in one NDA.
This patent has nine patent family members in nine countries.
Summary for Patent: 11,103,513
| Title: | Natural combination hormone replacement formulations and therapies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Brian A. Bernick, Peter H. R. Persicaner, Julia M. Amadio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | TherapeuticsMD Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/885,088 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,103,513 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 11,103,513: Scope, Claims, Expiration, and Bijuva Patent LandscapeUS Patent No. 11,103,513 protects methods of treating menopausal vasomotor symptoms with an oral, food-administered capsule containing 1 mg of 17β-estradiol and 100 mg of progesterone. The patent is directed to the Bijuva formulation and combines composition limitations with pharmacokinetic performance requirements. The strongest infringement risk applies to products that reproduce the capsule’s medium-chain lipid formulation, largely solubilized estradiol, partly solubilized and micronized progesterone, and the claimed exposure ranges. The patent does not broadly cover every estradiol/progesterone product. Its method claims require a particular patient population, administration with food, dosage form, formulation architecture, and pharmacokinetic result. What drug and product does US Patent 11,103,513 protect?US 11,103,513 is associated with the oral estradiol/progesterone product Bijuva, approved by the FDA under NDA 210366. Bijuva contains:
The formulation uses a lipid-based fill material. Estradiol is substantially solubilized. Progesterone is divided between a solubilized portion and a micronized, uniformly dispersed portion. The FDA approved Bijuva on October 10, 2018, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus. The progesterone component provides endometrial protection for women receiving systemic estrogen therapy.[1] What are the core claim elements of US 11,103,513?The patent contains 30 claims. Claims 1, 9, 12, and 17 are the principal independent claims. The remaining claims narrow those methods through additional patient, formulation, particle-size, ratio, and pharmacokinetic limitations. Claim 1: narrow closed-composition methodClaim 1 requires all of the following:
The use of “consisting of” in the fill-material definition makes claim 1 materially narrower than the claims using “comprising.” An accused product containing an additional fill-material component could raise a literal infringement issue under claim 1, although the effect would depend on claim construction and the role of the additional ingredient. Claim 9: broader fixed-formulation methodClaim 9 covers substantially the same formulation but uses “comprising” for the fill material and solubilizing agent. That language generally permits additional components, subject to the remaining limitations. Claim 9 also requires that no more than about 15% by weight of the progesterone is solubilized in the solubilizing agent. This creates a formulation constraint that is narrower than the broader independent formulation concept in claim 1. Claim 12: functional lipid-system methodClaim 12 moves away from named excipients and covers a functional formulation defined by:
Claim 12 is potentially important for design-around analysis because it is not limited to the specific 196 mg and 3 mg quantities recited in claims 1 and 9. Claim 17: broad composition-percentage methodClaim 17 defines the formulation using weight percentages:
This claim is commercially relevant because the formulation ranges can capture products with different absolute excipient quantities, provided the resulting capsule satisfies the drug-content, structural, administration, and pharmacokinetic limitations. What pharmacokinetic parameters are required by the patent?The claims use pharmacokinetic ranges as claim limitations. At least one listed parameter is required in independent claims 1, 9, 12, and 17.
The ranges appear to be derived from clinical pharmacokinetic data and are expressed as population or study-performance boundaries. In an infringement dispute, the testing protocol would be central. Relevant variables could include fed-state meal composition, sampling schedule, assay methodology, patient population, formulation batch, and statistical treatment of the measured values. A product with the same nominal drug amounts may avoid infringement if it does not produce the claimed exposure range. Conversely, a product with different excipient quantities could present risk under claims 12 or 17 if it produces the claimed pharmacokinetic profile and satisfies the structural limitations. How do the dependent claims narrow patent protection?The dependent claims create several narrower infringement pathways.
The particle-size limitations in claims 8 and 25 are particularly relevant to manufacturing. A generic manufacturer would need to characterize micronized progesterone by the same or a sufficiently comparable particle-size methodology. “X50” and “X90” can vary depending on laser-diffraction settings, dispersion conditions, and calculation method. When does US Patent 11,103,513 expire?The patent is part of a family directed to the estradiol/progesterone formulation and methods of use. Its ordinary patent-term endpoint is expected to fall in the same general period as the family’s November 2, 2032 expiration date, subject to any applicable patent-term adjustment, terminal disclaimer, or regulatory patent-term extension.
A patent expiration date should be confirmed against the current USPTO patent record and Orange Book listing before relying on it in a launch or transaction decision. Patent-term adjustment and terminal-disclaimer information control the operative date.[2] What is the Orange Book status of Bijuva?Bijuva is an FDA-approved prescription drug listed in the Orange Book under NDA 210366. The relevant regulatory protections are different from the patent protections:
Bijuva received three-year new clinical investigation exclusivity associated with the 2018 approval. That regulatory exclusivity does not extend through the patent term and would not, by itself, block an ANDA after the exclusivity period ended.[1,3] What Paragraph IV challenges and generic entry risks affect Bijuva?A generic applicant seeking approval before listed patent expiration would typically evaluate one or more certifications under the Hatch-Waxman framework:
The primary generic risk does not arise from the 1 mg/100 mg drug combination alone. It arises from reproducing the protected delivery system and achieving the claimed pharmacokinetic ranges. A generic applicant could pursue several strategies:
The product-specific PK limitations may complicate both sides’ positions. They can narrow the literal scope of the claims, but they can also make noninfringement difficult to establish if the proposed ANDA product is required to demonstrate bioequivalence to Bijuva. Which companies are challenging the Bijuva patent estate?Publicly available information must be separated into confirmed litigation and ordinary generic-development activity. An ANDA filing, tentative approval, or commercial generic listing does not by itself establish a filed Paragraph IV case. For US 11,103,513 specifically, the patent number, assignee, and claim text alone do not establish that a particular company has filed a Paragraph IV certification or that a federal patent case is pending. A litigation search must be performed at the patent, NDA, and district-court docket levels. The relevant parties may include the NDA holder, current patent owner, licensees, ANDA applicants, and authorized generic partners. The absence of a confirmed case tied to this patent in the supplied record should not be treated as proof that no Paragraph IV notice or settlement exists. What licensing and ownership issues affect the patent?The commercial rights associated with Bijuva have changed over time. TherapeuticsMD developed and commercialized the product before its women’s-health assets were transferred to or acquired by Mayne Pharma. The patent landscape should therefore distinguish:
Assignment records at the USPTO and FDA’s current NDA records are more reliable than historical press releases for determining who can enforce the patent. A license agreement may also allocate enforcement rights, royalties, settlement authority, and responsibility for Orange Book maintenance. How strong is the patent estate for Bijuva?The estate has moderate structural strength but is narrower than a basic composition patent. Strengths
Vulnerabilities
The patent is more difficult to design around than a claim limited only to exact excipient quantities, but it does not automatically block every oral estradiol/progesterone capsule. How does Bijuva compare with other menopausal hormone-therapy products?
Competitors using a different estrogen, progestogen, route, or separate-product regimen generally present lower direct infringement risk under US 11,103,513. A competing oral softgel containing the same hormone doses and lipid delivery approach presents the highest risk. What geographic coverage does the patent provide?US 11,103,513 provides protection only in the United States. It does not directly control:
Foreign family members must be assessed separately. The existence of a U.S. patent does not establish corresponding foreign rights, identical claim scope, or the same expiration date. National-phase prosecution, oppositions, annuities, terminal disclaimers, and local patent-term rules may produce materially different outcomes. What manufacturing and IP barriers matter most?The main technical barriers are:
The manufacturing process itself may create additional trade-secret or process-patent exposure even where the final product is designed to avoid the claims of US 11,103,513. Key Takeaways
Frequently Asked QuestionsDoes US 11,103,513 cover all estradiol and progesterone products?No. It targets specific oral capsule methods, formulation characteristics, administration with food, patient populations, and pharmacokinetic results. Can a generic avoid the patent by changing the surfactant?Potentially, but changing the surfactant alone may not avoid claims 12 or 17 if the alternative product still satisfies the broader functional limitations and PK requirements. Is progesterone particle size relevant to infringement?Yes. Claims 8 and 25 specifically address micronized progesterone with X50 and X90 particle-size thresholds. Does the patent cover transdermal estradiol with oral progesterone?Generally no, because the claims require a capsule containing both estradiol and progesterone administered orally with food. Is a biosimilar pathway available for Bijuva?No. Bijuva is a small-molecule drug. A competing product would generally use the ANDA pathway rather than the biosimilar pathway. References
More… ↓ |
Drugs Protected by US Patent 11,103,513
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | BIJUVA | estradiol; progesterone | CAPSULE;ORAL | 210132-001 | Oct 28, 2018 | RX | Yes | Yes | 11,103,513 | ⤷ Start Trial | TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,103,513
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 100562 | ⤷ Start Trial | |||
| Australia | 2015264003 | ⤷ Start Trial | |||
| Canada | 2947767 | ⤷ Start Trial | |||
| European Patent Office | 3145489 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
